NVS - Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps Analyst Says | Benzinga
Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency (CC).
Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18.
Biogen’s partner, Eisai Co Ltd (OTC:ESALY), has faced a delay in reaching the 10,000-patient mark for Leqembi despite strong demand.
In its third quarter financial results, Eisai disclosed that as of January 26, 2,000 patients were on treatment, with an estimated four times as many on a waiting list.
Logistics challenges are evident in the number of patients on the waiting list, but Eisai’s management sees this as a positive sign of ...